Citations (86)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Evelyn Walter, Matthäus Traunfellner, Martin Gleitsmann, Michaela Zalesak & Christian Helmenstein. (2023) The cost-of-illness and burden-of-disease of treatment-resistant depression in Austria. Journal of Medical Economics 26:1, pages 1432-1444.
Read now
Read now
Charles Ruetsch, Tigwa Davis, Joshua N Liberman, Dawn I Velligan, Delbert Robinson, Chris Jaeger, William Carpenter & Felica Forma. (2021) Prescriber Attitudes, Experiences, and Proclivities Toward Digital Medicine and How They Influence Adoption of Digital Medicine Platforms. Neuropsychiatric Disease and Treatment 17, pages 3715-3726.
Read now
Read now
Valentina Perrone, Diego Sangiorgi, Margherita Andretta, Giuseppe Ducci, Bruno Forti, Pier Cesare Francesa Morel, Marco Gambera, Giuseppe Maina, Claudio Mencacci, Francesco Saverio Mennini, Enrico Zanalda & Luca Degli Esposti. (2021) Healthcare Resource Consumption and Related Costs of Patients Estimated with Treatment-Resistant Depression in Italy. ClinicoEconomics and Outcomes Research 13, pages 629-635.
Read now
Read now
Holly Szukis, Kruti Joshi, Ahong Huang, Tony B. Amos, Li Wang & Carmela J. Benson. (2021) Economic burden of treatment-resistant depression among veterans in the United States. Current Medical Research and Opinion 37:8, pages 1393-1401.
Read now
Read now
Drishti Shah, Wanhong Zheng, Lindsay Allen, Wenhui Wei, Traci LeMasters, Suresh Madhavan & Usha Sambamoorthi. (2021) Using a machine learning approach to investigate factors associated with treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder. Current Medical Research and Opinion 37:5, pages 847-859.
Read now
Read now
Dominic Pilon, Swapna Karkare, Maryia Zhdanava, John J. Sheehan, Aurélie Côté-Sergent, Aditi Shah, Oliver J. Lopena, Patrick Lefebvre, Kruti Joshi & Leslie Citrome. (2021) Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy. Journal of Medical Economics 24:1, pages 1299-1308.
Read now
Read now
Qian Cai, John J. Sheehan, Bingcao Wu, Larry Alphs, Nancy Connolly & Carmela Benson. (2020) Descriptive analysis of the economic burden of treatment resistance in a major depressive episode. Current Medical Research and Opinion 36:2, pages 329-335.
Read now
Read now
Paul McCrone, Felicitas Rost, Leonardo Koeser, Iakovina Koutoufa, Stephanie Stephanou, Martin Knapp, David Goldberg, David Taylor & Peter Fonagy. (2018) The economic cost of treatment-resistant depression in patients referred to a specialist service. Journal of Mental Health 27:6, pages 567-573.
Read now
Read now
Yigizie Yeshaw & Andualem Mossie. (2017) Depression, anxiety, stress, and their associated factors among Jimma University staff, Jimma, Southwest Ethiopia, 2016: a cross-sectional study. Neuropsychiatric Disease and Treatment 13, pages 2803-2812.
Read now
Read now
Zheng-Yi Zhou, Shawn Sun, Pooja Chopra, Yichen Zhong, Todor Totev & James Signorovitch. (2015) Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Journal of Medical Economics 18:11, pages 919-929.
Read now
Read now
Anagha Nadkarni, Iftekhar Kalsekar, Min You, Robert Forbes & Tony Hebden. (2013) Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy. ClinicoEconomics and Outcomes Research 5, pages 49-57.
Read now
Read now
Eduard Vieta & Francesc Colom. (2011) Therapeutic options in treatment-resistant depression. Annals of Medicine 43:7, pages 512-530.
Read now
Read now
Sakina J. Rizvi, Madelin Donovan, Peter Giacobbe, Franca Placenza, Susan Rotzinger & Sidney H. Kennedy. (2011) Neurostimulation therapies for treatment resistant depression: A focus on vagus nerve stimulation and deep brain stimulation. International Review of Psychiatry 23:5, pages 424-436.
Read now
Read now
Articles from other publishers (73)
Enrico Pessina, Azzurra Martini, Fabiola Raffone & Vassilis Martiadis. (2023) Cariprazine augmentation in patients with treatment resistant unipolar depression who failed to respond to previous atypical antipsychotic add-on. A case-series. Frontiers in Psychiatry 14.
Crossref
Crossref
Jirada Prasartpornsirichoke, Nuttorn Pityaratstian, Chayanit Poolvoralaks, Naphat Sirinimnualkul, Tanaporn Ormtavesub, Nimmavadee Hiranwattana, Sasitorn Phonsit & Teerayuth Rungnirundorn. (2023) The prevalence and economic burden of treatment-resistant depression in Thailand. BMC Public Health 23:1.
Crossref
Crossref
Kimberlyn Maravet Baig-Ward, Manish Kumar Jha & Madhukar H. Trivedi. (2023) The Individual and Societal Burden of Treatment-Resistant Depression. Psychiatric Clinics of North America 46:2, pages 211-226.
Crossref
Crossref
Alix Arnaud, Jennifer Benner, Ellison Suthoff, Brian Werneburg, Marcia Reinhart, Matthew Sussman & Ronald C. Kessler. (2023) The impact of early remission on disease trajectory and patient outcomes in major depression disorder (MDD): A targeted literature review and microsimulation modeling approach based on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Journal of Affective Disorders 325, pages 264-272.
Crossref
Crossref
Prakash Adekkanattu, Mark Olfson, Leah C. Susser, Braja Patra, Veer Vekaria, Brandon J. Coombes, Lauren Lepow, Brian Fennessy, Alexander Charney, Euijung Ryu, Kurt D. Miller, Lifang Pan, Tenzin Yangchen, Ardesheer Talati, Priya Wickramaratne, Myrna Weissman, John Mann, Joanna M. Biernacka & Jyotishman Pathak. (2023) Comorbidity and healthcare utilization in patients with treatment resistant depression: A large-scale retrospective cohort analysis using electronic health records. Journal of Affective Disorders 324, pages 102-113.
Crossref
Crossref
Johan Lundberg, Thomas Cars, Sven-Åke Lööv, Jonas Söderling, Johan Sundström, Jari Tiihonen, Amy Leval, Anna Gannedahl, Carl Björkholm, Mikael Själin & Clara Hellner. (2023) Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study. JAMA Psychiatry 80:2, pages 167.
Crossref
Crossref
Yingying Huang, Ping Sun, Zhiguo Wu, Xiaoyun Guo, Xiaohui Wu, Jun Chen, Lu Yang, Xiao Wu & Yiru Fang. (2023) Comparison on the clinical features in patients with or without treatment-resistant depression: A National Survey on Symptomatology of Depression report. Psychiatry Research 319, pages 114972.
Crossref
Crossref
Jifei Sun, Yue Ma, Chunlei Guo, Zhongming Du, Limei Chen, Zhi Wang, Xiaojiao Li, Ke Xu, Yi Luo, Yang Hong, Xue Yu, Xue Xiao, Jiliang Fang & Jie Lu. (2023) Distinct patterns of functional brain network integration between treatment-resistant depression and non treatment-resistant depression: A resting-state functional magnetic resonance imaging study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 120, pages 110621.
Crossref
Crossref
Aly Akram, Medhat Al‐Sabahy, Ahmed Al‐Jedai, Hajer Almudaiheem, Mohamed Farghally, Ebtihaj Fallata, Osama Alibrahim, Tarek Shoukry, Sujata Basu, Danielle Chalouhi, Amr Elsharkawy & Omneya Mohamed. (2022) The clinical & economic burden of treatment‐resistant depression in the Gulf‐Cooperation Council: The Kingdom of Saudi Arabia, Kuwait and the United Arab Emirates. International Journal of Methods in Psychiatric Research.
Crossref
Crossref
Kristoffer Jarlov Jensen, Frederikke Hørdam Gronemann, Mikkel Zöllner Ankarfeldt, Espen Jimenez-Solem, Sarah Alulis, Jesper Riise, Nikolaj Bødker, Merete Osler & Janne Petersen. (2022) Healthcare resource utilization in patients with treatment-resistant depression—A Danish national registry study. PLOS ONE 17:9, pages e0275299.
Crossref
Crossref
Andrea Carta, Maria Del Zompo, Anna Meloni, Francesco Mola, Pasquale Paribello, Federica Pinna, Marco Pinna, Claudia Pisanu, Mirko Manchia, Alessio Squassina, Bernardo Carpiniello & Claudio Conversano. (2022) Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective. Clinical Drug Investigation 42:9, pages 733-746.
Crossref
Crossref
Jifei Sun, Yue Ma, Limei Chen, Zhi Wang, Chunlei Guo, Yi Luo, Deqiang Gao, Xiaojiao Li, Ke Xu, Yang Hong, Xiaobing Hou, Jing Tian, Xue Yu, Hongxing Wang, Jiliang Fang & Xue Xiao. (2022) Altered Brain Function in Treatment-Resistant and Non-treatment-resistant Depression Patients: A Resting-State Functional Magnetic Resonance Imaging Study. Frontiers in Psychiatry 13.
Crossref
Crossref
Xiaohui Zhao, Swapna Karkare, Abigail I. Nash, John J. Sheehan, Maya Aboumrad, Aimee M. Near, Tania Banerji & Kruti Joshi. (2022) Characteristics and current standard of care among veterans with major depressive disorder in the United States: A real-world data analysis. Journal of Affective Disorders 307, pages 184-190.
Crossref
Crossref
Frederikke Hørdam Gronemann, Thomas Lund, Louise Lindholdt, Kathrine Bang Madsen, Martin Balslev Jørgensen, Merete Nordentoft & Merete Osler. (2022) Treatment-resistant depression and labor market affiliation in the Danish welfare society: a register-based study. Social Psychiatry and Psychiatric Epidemiology 57:6, pages 1189-1199.
Crossref
Crossref
Michał Sobstyl, Anna Kupryjaniuk, Marek Prokopienko & Marcin Rylski. (2022) Subcallosal Cingulate Cortex Deep Brain Stimulation for Treatment-Resistant Depression: A Systematic Review. Frontiers in Neurology 13.
Crossref
Crossref
B. Gillain, G. Degraeve, T. Dreesen, G. De Bruecker, E. Buntinx, D. Beke, C. Kestens, E. Valassopoulou, F. Verhelst, E. Peeters, S. Pype, C. De Vos, D. Strens & I. Vandersmissen. (2021) Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium. PharmacoEconomics - Open 6:2, pages 293-302.
Crossref
Crossref
Bernice N. Yau, Carola Rong, J. Chase Findley & Salih Selek. (2021) A Novel Refractory Mood Disorders and Electroconvulsive Therapy Elective for Medical Students: Fighting Stigma through Experience. Psychiatric Quarterly 92:4, pages 1541-1548.
Crossref
Crossref
Giulio Perugi, Paola Calò, Sergio De Filippis, Gianluca Rosso, Antonio Vita, Marina Adami, Giuseppe Ascione, Joachim Morrens & Dario Delmonte. (2021) Clinical Features and Outcomes of 124 Italian Patients With Treatment Resistant Depression: A Real-World, Prospective Study. Frontiers in Psychiatry 12.
Crossref
Crossref
Sjoerd M. van Belkum, Marrit K. de Boer, Esther M. Opmeer, Rudie Kortekaas, Tim Mulder, Frank Woonings, H.J. Rogier Hoenders, Hans Kamphuis, André Aleman & Robert A. Schoevers. (2021) No antidepressant effects of low intensity transcranial pulsed electromagnetic fields for treatment resistant depression. Journal of Affective Disorders 294, pages 679-685.
Crossref
Crossref
Jason Ng, Joshua D. Rosenblat, Leanna M.W. Lui, Kayla M. Teopiz, Yena Lee, Orly Lipsitz, Rodrigo B. Mansur, Nelson B. Rodrigues, Flora Nasri, Hartej Gill, Danielle S. Cha, Mehala Subramaniapillai, Roger C. Ho, Bing Cao & Roger S. McIntyre. (2021) Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review. Journal of Affective Disorders 293, pages 285-294.
Crossref
Crossref
Yun Wu, Dongbao Zhao, Jianwei Guo, Yingsi Lai, Lijin Chen, Sihui Jin & Yixiang Huang. (2021) Economic Burden of Depressive Symptoms Conditions among Middle-Aged and Elderly People with Hypertension in China. International Journal of Environmental Research and Public Health 18:19, pages 10009.
Crossref
Crossref
Felicia Forma, Jennifer Clerie, Tigwa Davis, Kelly Clovie & Charles Ruetsch. (2020) The Association between Patient Activation and Outcomes among Severely Mentally Ill Patients. The Journal of Behavioral Health Services & Research 48:3, pages 382-399.
Crossref
Crossref
Linda Xing Yu Liu, Marina Golts & Virginia Fernandes. (2021) Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine. Pharmacy 9:3, pages 118.
Crossref
Crossref
Drishti Shah, Lindsay Allen, Wanhong Zheng, Suresh S. Madhavan, Wenhui Wei, Traci J. LeMasters & Usha Sambamoorthi. (2021) Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US. PharmacoEconomics 39:6, pages 639-651.
Crossref
Crossref
Alix Arnaud, Ellison Suthoff, Rita M. Tavares, Xuan Zhang & Aditi J. Ravindranath. (2021) The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder. PharmacoEconomics 39:6, pages 691-706.
Crossref
Crossref
Urvi Desai, Noam Y Kirson, Andrea Guglielmo, Hoa H Le, Timothy Spittle, Joshua Tseng-Tham, May Shawi & John J Sheehan. (2021) Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression. Journal of Comparative Effectiveness Research 10:5, pages 393-407.
Crossref
Crossref
Antoine Yrondi, Djamila Bennabi, Emmanuel Haffen, Delphine Quelard, Ludovic Samalin, Julia Maruani, Etienne Allauze, Damien Pierre, Thierry Bougerol, Vincent Camus, Thierry D’Amato, Olivier Doumy, Jérôme Holtzmann, Christophe Lançon, Fanny Moliere, Rémi Moirand, Isabel Nieto, Raphaëlle Richieri, Mathilde Horn, Laurent Schmitt, Florian Stephan, Jean-Baptiste Genty, Guillaume Vaiva, Michel Walter, Philippe Courtet, Marion Leboyer, Pierre-Michel Llorca, Sophie Marguet, Nathalie Dennis, Dominique Schaetz, Wissam El-Hage & Bruno Aouizerate. (2020) Treatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort. Brain Sciences 10:12, pages 962.
Crossref
Crossref
Roger S. McIntyre, Brad Millson & G. Sarah Power. (2020) Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization. Journal of Affective Disorders 277, pages 30-38.
Crossref
Crossref
Aki Shiozawa, Sari Hopson, Rupali Fuldeore, Matthias Stoelzel, Daniel Ng & John Hairston. (2020) Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case–Control Cohort Analysis. Advances in Therapy 37:11, pages 4599-4613.
Crossref
Crossref
Gang Li, Ling Zhang, Allitia DiBernardo, Grace Wang, John J. Sheehan, Kwan Lee, Johan Reutfors & Qiaoyi Zhang. (2020) A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients. PLOS ONE 15:9, pages e0238843.
Crossref
Crossref
Milaine Roet, Jackson Boonstra, Erdi Sahin, Anne E.P. Mulders, Albert F.G. Leentjens & Ali Jahanshahi. (2020) Deep Brain Stimulation for Treatment-Resistant Depression: Towards a More Personalized Treatment Approach. Journal of Clinical Medicine 9:9, pages 2729.
Crossref
Crossref
Maryia ZhdanavaHarsh KuvadiaKruti JoshiElla DalyDominic PilonCarmine RossiLaura MorrisonPatrick LefebvreCraig Nelson. (2020) Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions. Journal of Managed Care & Specialty Pharmacy 26:8, pages 996-1007.
Crossref
Crossref
Patricio Riva-Posse. (2020) Why is deep brain stimulation for treatment-resistant depression a needed treatment option?. Brazilian Journal of Psychiatry 42:4, pages 344-346.
Crossref
Crossref
Anshu ShresthaMeaghan RoachKruti JoshiJohn J. SheehanProdyumna GoutamKatie EversonKristin HeerleinAnupam B. Jena. (2020) Incremental Health Care Burden of Treatment-Resistant Depression Among Commercial, Medicaid, and Medicare Payers. Psychiatric Services 71:6, pages 593-601.
Crossref
Crossref
Selma Ozcan, Sakir Gica & Huseyin Gulec. (2020) Suicidal behavior in treatment resistant major depressive disorder patients treated with transmagnetic stimulation(TMS) and its relationship with cognitive functions. Psychiatry Research 286, pages 112873.
Crossref
Crossref
Carmela Benson, Holly Szukis, John J. Sheehan, Larry Alphs & Huseyin Yuce. (2020) An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant Depression. The American Journal of Geriatric Psychiatry 28:3, pages 350-362.
Crossref
Crossref
Dominic Pilon, Holly Szukis, Kruti Joshi, David Singer, John J. Sheehan, Jennifer W. Wu, Patrick Lefebvre & Paul Greenberg. (2019) US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study. PharmacoEconomics - Open 4:1, pages 119-131.
Crossref
Crossref
Bradley N. Gaynes, Linda Lux, Gerald Gartlehner, Gary Asher, Valerie Forman‐Hoffman, Josh Green, Erin Boland, Rachel P. Weber, Charli Randolph, Carla Bann, Emmanuel Coker‐Schwimmer, Meera Viswanathan & Kathleen N. Lohr. (2019) Defining treatment‐resistant depression. Depression and Anxiety 37:2, pages 134-145.
Crossref
Crossref
Kathrine Bang Madsen, Liselotte Vogdrup Petersen, Oleguer Plana-Ripoll, Katherine L. Musliner, Jean-Christophe Philippe Debost, Frederikke Hordam Gronemann, Preben Bo Mortensen & Trine Munk-Olsen. (2020) Early labor force exits in patients with treatment-resistant depression: an assessment of work years lost in a Danish nationwide register-based cohort study. Therapeutic Advances in Psychopharmacology 10, pages 204512532097379.
Crossref
Crossref
Dena H. Jaffe, Benoit Rive & Tom R. Denee. (2019) The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry 19:1.
Crossref
Crossref
Dominic Pilon, Kruti Joshi, John J. Sheehan, Miriam L. Zichlin, Peter Zuckerman, Patrick Lefebvre & Paul E. Greenberg. (2019) Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. PLOS ONE 14:10, pages e0223255.
Crossref
Crossref
Jay Lin, Holly Szukis, John J. Sheehan, Larry Alphs, Brandy Menges, Melissa Lingohr‐Smith & Carmela Benson. (2019) Economic Burden of Treatment‐Resistant Depression Among Patients Hospitalized for Major Depressive Disorder in the United States. Psychiatric Research and Clinical Practice 1:2, pages 68-76.
Crossref
Crossref
Matthew SussmanAmy K. O’sullivanAnkit ShahMark OlfsonJoseph Menzin. (2019) Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System. Journal of Managed Care & Specialty Pharmacy 25:7, pages 823-835.
Crossref
Crossref
Hsing-Jung Li, Chao-Chan Kuo, Ying-Chun Li, Kuan-Yi Tsai & Hung-Chi Wu. (2019) Depression may not be a risk factor for mortality in stroke patients with nonsurgical treatment. Medicine 98:22, pages e15753.
Crossref
Crossref
Dominic Pilon, John J Sheehan, Holly Szukis, David Singer, Philippe Jacques, Dominique Lejeune, Patrick Lefebvre & Paul E Greenberg. (2019) Medicaid spending burden among beneficiaries with treatment-resistant depression. Journal of Comparative Effectiveness Research 8:6, pages 381-392.
Crossref
Crossref
Christoforos Iraklis Giakoumatos & David Osser. (2019) The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Unipolar Nonpsychotic Depression. Harvard Review of Psychiatry 27:1, pages 33-52.
Crossref
Crossref
Karissa M. Johnston, Lauren C. Powell, Ian M. Anderson, Shelagh Szabo & Stephanie Cline. (2019) The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. Journal of Affective Disorders 242, pages 195-210.
Crossref
Crossref
Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart & Robert A. Schoevers. 2019. Treatment Resistance in Psychiatry. Treatment Resistance in Psychiatry
3
24
.
D. Richard Martini & Tammer Attallah. 2019. Psychiatric Nonadherence. Psychiatric Nonadherence
3
16
.
Thomas R Lynch, Roelie J Hempel, Ben Whalley, Sarah Byford, Rampaul Chamba, Paul Clarke, Susan Clarke, David Kingdon, Heather O’Mahen, Bob Remington, Sophie C Rushbrook, James Shearer, Maggie Stanton, Michaela Swales, Alan Watkins & Ian T Russell. (2018) Radically open dialectical behaviour therapy for refractory depression: the RefraMED RCT. Efficacy and Mechanism Evaluation 5:7, pages 1-112.
Crossref
Crossref
Isidoor O. Bergfeld, Mariska Mantione, Martijn Figee, P. Richard Schuurman, Anja Lok & Damiaan Denys. (2018) Treatment-resistant depression and suicidality. Journal of Affective Disorders 235, pages 362-367.
Crossref
Crossref
Daniel Fife, Jenna Reps, M. Soledad Cepeda, Paul Stang, Margaret Blacketer & Jaskaran Singh. (2018) Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition. Heliyon 4:7, pages e00707.
Crossref
Crossref
Mark OlfsonTony B. AmosCarmela BensonJacquelyn McRaeSteven C. Marcus. (2018) Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression. Journal of Managed Care & Specialty Pharmacy 24:3, pages 226-236.
Crossref
Crossref
Jörg Mahlich, Sunny Tsukazawa & Frank Wiegand. (2017) Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study. Drugs - Real World Outcomes 5:1, pages 35-43.
Crossref
Crossref
Angela Merkl, Sabine Aust, Gerd-Helge Schneider, Veerle Visser-Vandewalle, Andreas Horn, Andrea A. Kühn, Jens Kuhn & Malek Bajbouj. (2018) Deep brain stimulation of the subcallosal cingulate gyrus in patients with treatment-resistant depression: A double-blinded randomized controlled study and long-term follow-up in eight patients. Journal of Affective Disorders 227, pages 521-529.
Crossref
Crossref
Maryam I. Al ShirawiSidney H. KennedyKeith T. HoRoisin ByrneJonathan Downar. (2017) Oral Ketamine in Treatment-Resistant Depression. Journal of Clinical Psychopharmacology 37:4, pages 464-467.
Crossref
Crossref
Daniel Fife, Yu Feng, Michael Yao-Hsien Wang, Chee-Jen Chang, Chia-Yih Liu, Hsiao-Ting Juang, Wesley Furnback, Jaskaran Singh & Bruce Wang. (2017) Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Research 252, pages 277-283.
Crossref
Crossref
Roger S. McIntyre, Daisy Ng-Mak, Chien-Chia Chuang, Rachel Halpern, Pankaj A. Patel, Krithika Rajagopalan & Antony Loebel. (2017) Major depressive disorder with subthreshold hypomanic (mixed) features: A real-world assessment of treatment patterns and economic burden. Journal of Affective Disorders 210, pages 332-337.
Crossref
Crossref
Matthew Sussman, Jeffrey Yu, Siddhesh A. Kamat, Ann Hartry, Susan Legacy, Ruth Duffy & Myrlene Sanon Aigbogun. (2017) Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder. Journal of Affective Disorders 207, pages 54-62.
Crossref
Crossref
Gin S Malhi & Yulisha Byrow. (2016) Is treatment-resistant depression a useful concept?. Evidence Based Mental Health 19:1, pages 1-3.
Crossref
Crossref
Peter M. Haddad, Peter S. Talbot, Ian M. Anderson & R. Hamish McAllister-Williams. (2015) Managing inadequate antidepressant response in depressive illness. British Medical Bulletin 115:1, pages 183-201.
Crossref
Crossref
C. Anthony Altar, Joseph Carhart, Josiah D. Allen, Daniel Hall-Flavin, Joel Winner & Bryan Dechairo. (2015) Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies. Complex Psychiatry 1:3, pages 145-155.
Crossref
Crossref
Sakina J Rizvi, Etienne Grima, Mary Tan, Susan Rotzinger, Peter Lin, Roger S McIntyre & Sidney H Kennedy. (2014) Treatment-Resistant Depression in Primary Care across Canada. The Canadian Journal of Psychiatry 59:7, pages 349-357.
Crossref
Crossref
Sandra Hollinghurst, Fran E. Carroll, Anna Abel, John Campbell, Anne Garland, Bill Jerrom, David Kessler, Willem Kuyken, Jill Morrison, Nicola Ridgway, Laura Thomas, Katrina Turner, Chris Williams, Tim J. Peters, Glyn Lewis & Nicola Wiles. (2018) Cost-effectiveness of cognitive–behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. British Journal of Psychiatry 204:1, pages 69-76.
Crossref
Crossref
Laura Thomas, David Kessler, John Campbell, Jill Morrison, Tim J Peters, Chris Williams, Glyn Lewis & Nicola Wiles. (2013) Prevalence of treatment-resistant depression in primary care: cross-sectional data. British Journal of General Practice 63:617, pages e852-e858.
Crossref
Crossref
Adrienne O’Neil, Michael Berk, Catherine Itsiopoulos, David Castle, Rachelle Opie, Josephine Pizzinga, Laima Brazionis, Allison Hodge, Cathrine Mihalopoulos, Marya Lou Chatterton, Olivia M Dean & Felice N Jacka. (2013) A randomised, controlled trial of a dietary intervention for adults with major depression (the “SMILES” trial): study protocol. BMC Psychiatry 13:1.
Crossref
Crossref
Nicole Kubitz, Maneesha Mehra, Ravi C. Potluri, Nitesh Garg & Nicole Cossrow. (2013) Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US Commercial Claims Database. PLoS ONE 8:10, pages e76882.
Crossref
Crossref
J Winner, J D Allen, C Anthony Altar & A Spahic-Mihajlovic. (2013) Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Translational Psychiatry 3:3, pages e242-e242.
Crossref
Crossref
Beatrice Alinka Lepine, Ricardo Alberto Moreno, Rodolfo Nunes Campos & Bernard François Couttolenc. (2012) Treatment-Resistant Depression Increases Health Costs and Resource Utilization. Revista Brasileira de Psiquiatria 34:4, pages 379-388.
Crossref
Crossref
Carl Erik Fisher, Laura B. Dunn, Paul P. Christopher, Paul E. Holtzheimer, Yan Leykin, Helen S. Mayberg, Sarah H. Lisanby & Paul S. Appelbaum. (2012) The ethics of research on deep brain stimulation for depression: decisional capacity and therapeutic misconception. Annals of the New York Academy of Sciences 1265:1, pages 69-79.
Crossref
Crossref
Renrong Wu, David E. Kemp, Martha Sajatovic, Jingping Zhao, Joseph R. Calabrese & Keming Gao. (2011) Communication of Potential Benefits and Harm to Patients and Payers in Psychiatry: A Review and Commentary. Clinical Therapeutics 33:12, pages B62-B76.
Crossref
Crossref
Yonghua Jing, Iftekhar Kalsekar, Suellen M. Curkendall, Ginger S. Carls, Erin Bagalman, Robert A. Forbes, Tony Hebden & Michael E. Thase. (2011) Intent-to-Treat Analysis of Health Care Expenditures of Patients Treated With Atypical Antipsychotics as Adjunctive Therapy in Depression. Clinical Therapeutics 33:9, pages 1246-1257.
Crossref
Crossref
M. Tarrants, M. Oleen-Burkey, J. Castelli-Haley & M. J. Lage. (2011) The Impact of Comorbid Depression on Adherence to Therapy for Multiple Sclerosis. Multiple Sclerosis International 2011, pages 1-10.
Crossref
Crossref